Nanoparticle-mediated surfactant therapy in patients with severe COVID-19: a perspective.
J Mater Chem B
; 9(35): 6988-6993, 2021 09 15.
Article
in English
| MEDLINE | ID: covidwho-1262017
ABSTRACT
Coronavirus disease 2019 (COVID-19) is an RNA virus-based disease that can be deadly. For critically ill patients, mechanical ventilation is an important life-saving treatment. However, mechanical ventilation shows a trade-off between supporting respiratory function and ventilator-induced lung injury (VILI). Surfactant therapy is a medical administration of exogenous surfactant to supplement or replace deficient or dysfunctional endogenous surfactant. Surfactant therapy can be used to postpone or shorten the use of mechanical ventilation to minimize or avoid VILI, because surfactants can reduce surface tension, improve lung compliance, and enhance oxygenation. In addition, nanotechnology can be applied to improve the therapeutic effect and reduce the adverse effects of surfactants. In this perspective, we discussed how nanoparticles deliver surfactants through intravenous injection and inhalation to the expected lung disease regions where surfactants are mostly needed, and discussed the prospects of nanoparticle-mediated surfactant therapy in the treatment of patients with severe COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pulmonary Surfactants
/
Drug Carriers
/
Nanoparticles
/
COVID-19 Drug Treatment
Limits:
Animals
/
Humans
Language:
English
Journal:
J Mater Chem B
Year:
2021
Document Type:
Article
Affiliation country:
D1tb00730k
Similar
MEDLINE
...
LILACS
LIS